All In MedTech

Device Trial Radar · NCT07029646

Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen Pathology

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Jul 1, 2025

Primary completion

Apr 30, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Peking University Cancer Hospital & InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 19, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess whether cell microscopic imaging can accurately determine the tumor-free status of surgical margins in breast cancer patients undergoing breast-conserving surgery. This study involves female patients aged 18-70 years with breast cancer who are candidates for breast-conserving surgery. The main question it aims to answer is: \- Can cell microscopic imaging provide accurate intraoperative assessment of surgical margins compared to standard frozen pathology? Researchers will compare the results of cell microscopic imaging to those of standard frozen pathology and paraffin pathology to see if the new imaging technology can effectively and quickly determine whether surgical margins are free of cancer cells. Participants will: * Undergo breast-conserving surgery with standard pathological assessments. * Have their surgical margins evaluated using cell microscopic imaging during the operation. * Be monitored for postoperative recovery at regular intervals (2 weeks, 3 months, 6 months, and 12 months) after the surgery.

Conditions

  • Breast-Conserving Surgery
  • Breast Carcinoma
  • Margins in the Specimen

Interventions

  • EndoScell™ intraoperative handheld microscopeDevice

    The research instrument used is the EndoScell™ intraoperative handheld microscope, which employs the principle of epifluorescence. It is a miniaturized microscope that reduces the size of a traditional large optical microscope by approximately a thousand times. It is the world's first handheld micrometer-level intraoperative real-time cell imaging probe microscope. This microscope is equipped with high-definition, real-time, anti-shake, and full-coverage scanning features. It can rapidly investigate the structure and cell morphology of tissues in real-time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AccuracyTime frame: Within 7 days after the operation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital & Institute

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.